(Q24519008)

2 July 2017

Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy (English)

1 reference

2 July 2017

Pharmacodynamic Evaluation of Factors Associated with the Development of Bacterial Resistance in Acutely Ill Patients during Therapy (English)

0 references

0 references

1 reference

3

Sujata M. Bhavnani

0 references

Jerome J. Schentag

7

object named as

Jerome J. Schentag

0 references

author name string

J K Thomas

1

1 reference

2 July 2017

A Forrest

2

1 reference

2 July 2017

S M Bhavnani

3

1 reference

2 July 2017

J M Hyatt

4

1 reference

2 July 2017

A Cheng

5

1 reference

2 July 2017

C H Ballow

6

1 reference

2 July 2017

J J Schentag

7

1 reference

2 July 2017

Jennifer K. Thomas

1

0 references

Alan Forrest

2

0 references

Judith M. Hyatt

4

0 references

Angela Cheng

5

0 references

Charles H. Ballow

6

0 references

language of work or name

English

0 references

publication date

1 March 1998

1 reference

Antimicrobial Agents and Chemotherapy

2 July 2017

1 reference

2 July 2017

42

1 reference

2 July 2017

3

1 reference

2 July 2017

521-527

1 reference

A functional classification scheme for beta-lactamases and its correlation with molecular structure

2 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105492

Antibiotic resistance: a view from the pharmaceutical industry

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105492

Pharmacokinetics and pharmacodynamics of antibiotics in otitis media

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105492

Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105492

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105492

Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105492

Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105492

Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105492

The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105492

Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105492

Cefmenoxime Efficacy, Safety, and Pharmacokinetics in Critical Care Patients with Nosocomial Pneumonia

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105492

Antimicrobial-drug resistance

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105492

Mathematical Examination of Dual Individualization Principles (I): Relationships between AUC above MIC and Area under the Inhibitory Curve for Cefmenoxime, Ciprofloxacin, and Tobramycin

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105492

Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105492

A program package for simulation and parameter estimation in pharmacokinetic systems

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105492

Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105492

Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105492

Trends in antibiotic utilization and bacterial resistance. Report of the National Nosocomial Resistance Surveillance Group

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105492

Mathematical examination of dual individualization principles (II): The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105492

Role for Dual Individualization with Cefmenoxime

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105492

AUIC--the universal parameter within the constraint of a reasonable dosing interval

29 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/9517926

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A Bayesian extension of the minimum AIC procedure of autoregressive model fitting

1 reference

Crossref

https://api.crossref.org/works/10.1128%2FAAC.42.3.521

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1128/AAC.42.3.521

0 references

OpenCitations bibliographic resource ID

2999862

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

0 references

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference